|22.58||+1.34 / +6.31%|
As of 3:59pm ET
|22.58||0.00 / 0.00%|
The 8 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 21.00, with a high estimate of 26.00 and a low estimate of 7.00. The median estimate represents a -7.00% decrease from the last price of 22.58.
The current consensus among 8 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.